News for Addex Therapeutics Ltd (ADXN)

Addex Therapeutics (ADXN) has revealed promising findings regarding the anti-tussive effectiveness of its innovative gamma-aminobutyric acid sub-type B receptor

**media[643887]**

Addex Therapeutics, known by its ticker ADXN, has entered into a strategic partnership with Sinntaxis AB. This collaboration focuses on an exclusive license con

**media[609719]**

Series A Financing: USD65 million raised for Neurosterix, led by Perceptive Advisors.Cash Received: CHF5 million in cash from the Neurosterix transaction.Equit

Addex Therapeutics Ltd (NASDAQ:ADXN) Q4 2024 Earnings Conference Call April 25, 2025 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board Director...

**media[605223]**

**media[603870]**

Addex Therapeutics (ADXN) disclosed that it has reacquired all development and commercialization rights to ADX71149 after the termination of its collaboration w

**media[597522]**

**media[508865]**

Revenue: CHF0.1 million in Q3 2024, compared to CHF0.3 million in Q3 2023.R&D Expenses: CHF0.2 million in Q3 2024, decreased by CHF0.3 million from Q3 2023.G&A

Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board Director...

Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

**media[461671]**

Texas-based Genprex, Inc. (GNPX), a clinical-stage gene therapy company is up over 103 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of iRhythm Technologies, Inc. IRTC rose sharply in today's pre-market trading after the company announced that it was granted FDA clearance for its 510(k...

Addex Therapeutics (ADXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Series A Financing: USD 63 million led by Perceptive Advisors.Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest.Milestone Payments: Up to